



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 14.09.2020

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 14.09.2020 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2020. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2020. **(Enclosed)**

The meeting concluded at 06.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Koni Reddy

S. Koni Reddy
Whole-time Director & CFO
DIN: 02829319



Encl: as above



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2020

[Rs. in Lakhs]

Particulars	Quarterly ended		Year ended	
	30-Jun-20 (UnAudited)	31-Mar-20 (Audited)	30-Jun-19 (UnAudited)	31-Mar-20 (Audited)
I Revenue from Operations				
a. Net sales from Operations	1,820.32	1,302.82	1,331.07	5,133.89
b. Other Operating Income	2.15	4.55	3.15	12.01
II Other Income				
III Total Revenue (I+II)	1,822.48	1,307.37	1,334.22	5,145.89
IV Expenses				
a. Cost of Material Consumed	1,497.57	1,116.82	1,094.90	4,206.02
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	96.72	20.65	21.30	51.72
c. Employees Benefit Expenses	87.00	84.78	81.36	350.72
d. Finance Costs	43.91	26.96	42.69	154.37
e. Depreciation and Amortisation expense	31.73	36.28	36.39	146.39
f. Other expenses	43.20	48.19	39.30	191.03
Total Expenses	1,800.12	1,292.38	1,315.93	5,100.25
Profit/ (Loss) before Exceptional item and tax (III-IV)	22.352	14.99	18.30	45.65
V Exceptional Items				
VI Profit/ (Loss) before tax (V-VI)	22.35	14.99	18.30	45.65
VII Tax Expense:				
a. Current tax	5.81	3.28	4.87	12.82
b. Deferred tax charge/credit	5.46	3.03	4.68	11.91
VIII Profit/ (Loss) for the period (VII-VIII)	0.36	0.25	0.19	0.91
IX Other Comprehensive Income				
Items that will not be reclassified to profit or loss	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	16.54	11.72	13.43	32.83
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38
XII Other Equity	1,490.62	1,474.08	1,444.223	1,474.082
XIII Earnings per share (of Rs. 10 each)				
a. Basic (in Rs)	0.189	0.13	0.15	0.38
b. Diluted (in Rs)	0.189	0.13	0.15	0.38

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th September, 2020.
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.
Note: The figures for the qtr ended March 31, 2020 are balancing figures between the Audited figures of the full financial year ended 31, March 2020 & the published year to date figures upto 9 months ended Dec 31, 2019.
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

For CONCORD DRUGS LIMITED

S. N. Sanyal

Chairman

By Order of the Board
For Concord Drugs Limited

S. N. Sanyal
Managing Director

DIN: 01764665

Place: Hyderabad

Date: September 14, 2020



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2020, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N.G Rao and Associates
Chartered Accountants
FRN: 009399S



(G Nageswara Rao)
Partner
MNo: 207300
UDIN No: 20207300AAAAOI4010

Place: Hyderabad
Date: 14-09-2020.